The Hansen Group investigates the human genome and the human global microbiome to characterize the impact of these genomes on health and disease and to identify interactions between the host and the microbiome. The findings can lead to potent translational strategies for prevention and treatment of metabolic disease.
In the molecular understanding of metabolic diseases a major gap exists between basic genetic and microbiome discoveries and their impact on physiology and the potential for clinical translation. The Hansen Group aims to bridge this gap by bringing together genomics discovery and epidemiology, culminating in a physiological and clinical understanding of genomics in metabolism.
To study the role of selected genetic variants in human metabolism, we perform physiology and intervention studies based on recruit-by-genotype principles. We also investigate families and populations with extreme metabolic phenotypes and perform physiology and intervention studies in selected individuals with specific microbiome signatures. Finally, we investigate targeted clinical management of carriers of selected high-impact variations in the human genome.